Cyclosporin for Inflammatory Bowel Disease: Mechanisms and Possible Actions

References

• Borel J F, Feurer C, Gubler H U, Stähelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976; 6: 468–75
   PubMedGoogle Scholar
• von Wartburg A, Traber R. Chemistry of the natural cyclosporin metabolites. Prog Allergy 1986; 38: 28–45
   PubMedGoogle Scholar
• Borel J F, Feurer C, Magnee C, Stahelin H. Effect of the new antilymphocyte peptide cyclosporin A in animals. Immunology 1977; 32: 1017–25
   PubMed Web of Science ®Google Scholar
• Bendtzen K. Biological properties of interleukins. Allergy 1983; 38: 219–26
   PubMed Web of Science ®Google Scholar
• Bendtzen K. Interleukin 1, interleukin 6 and tumour necrosis factor in infection, inflammation and immunity. Immunol Lett 1988; 19: 183–92
   PubMed Web of Science ®Google Scholar
• Bendtzen K. Immune hormones (cytokines); pathogenic role in autoimmune rheumatic and endocrine diseases. Autoimmunity 1989; 2: 177–89
   PubMed Web of Science ®Google Scholar
• Bendtzen K. Cellular and molecular processes underlying immunoinfiammation. Clinical impact of the monitoring of allergic inflammation, S Ahlstedt, P Mattson, J Thorell, P Venge. Academic Press, London 1991; 187–200
   Google Scholar
• Tosato G, Pike S E, Koski I R, Blaese R M. Selective inhibition of immunoregulatory cell functions by cyclosporin A. J Immunol 1982; 128: 1986–91
   PubMed Web of Science ®Google Scholar
• Hess A D, Tutschka P J. Effect of cyclosporin A on human lymphocyte responses in vitro. I. CsA allows for the expression of alloantigen-activated suppressor cells while preferentially inhibiting the induction of cytolytic effector lymphocytes in MLR. J Immunol 1980; 124: 2601–8
   PubMed Web of Science ®Google Scholar
• Koizumi M, King N, Lobb R, Benjamin C, Podolsky D K. Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology 1992; 103: 840–7
   PubMed Web of Science ®Google Scholar
• Malizia G, Calabrese A, Cottone M, et al. Expression of leucocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease. Gastroenterology 1991; 100: 150–9
   PubMed Web of Science ®Google Scholar
• Brynskov J, Nielsen O H, Ahnfelt-Rønne I, Bendtzen K. Cytokines in inflammatory bowel disease. Scand J Gastroenterol 1992; 27: 897–906
   PubMed Web of Science ®Google Scholar
• Hu-Li J, Shevach E M, Mizuguchi J, Ohara J, Mosmann T, Paul W E. B cell stimulatory factor 1 (interleukin 4) is a potent costimulatory for normal resting T lymphocytes. J Exp Med 1987; 165: 157–72
   PubMed Web of Science ®Google Scholar
• Dinarello C A, Cannon J G, Wolff S M, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986; 163: 1433–50
   PubMed Web of Science ®Google Scholar
• van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253–78
   PubMed Web of Science ®Google Scholar
• Cantrell D A, Smith K A. The interleukin-2 T-cell system. A new cell growth model. Science 1984; 224: 1312–6
   PubMed Web of Science ®Google Scholar
• Palacios R. Mechanism of T cell activation: role and functional relationship of HLA-DR antigens and interleukins. Immunol Rev 1982; 63: 73–110
   PubMed Web of Science ®Google Scholar
• Ruscetti F W, Gallo R C. Human T-lymphocyte growth factor: regulation of growth and function of T lymphocytes. Blood 1981; 57: 379–94
   PubMed Web of Science ®Google Scholar
• Smith K A. The two-chain structure of high-affinity IL-2 receptors Immunol Today 1987; 8: 8–11
   Google Scholar
• Uchiyama T, Nelson D L, Fleisher T A, Waldman T A. A monoclonal antibody (anti-tac) reactive with activated and functionally mature human T-cells. II. Expression of Tac antigens on activated cytotoxic killer T cells, suppressor cells, and on one of the two types of helper T cells. J Immunol 1981; 126: 1398–403
   PubMed Web of Science ®Google Scholar
• Rubin L A, Kurman C C, Fritz M E, et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985; 135: 3172–7
   PubMed Web of Science ®Google Scholar
• Rubin L A, Jay G, Nelson D L. The released interleukin 2 receptor binds interleukin 2 efficiently. J Immunol 1986; 137: 3841–4
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Petersen J. Effects of cyclosporin A (CyA) and methylprednisolone (MP) on the immune response. I. T-cell-activating factor (IL-1) abrogates CyA- but not MP-induced suppression of antigen-induced lymphokine production. Immunol Lett 1982; 5: 79–83
   PubMedGoogle Scholar
• Hess A D, Tutschka P J, Santos G W. Effect of cyclosporin on the induction of cytotoxic T lymphocytes: role of interleukin 1 and interleukin 2. Transplant Proc 1983; 15(Suppl 1)2248–58
   Google Scholar
• Palacios R, Moller G. Cyclosporin A blocks receptors for HLA-DR antigens on T cells. Nature 1981; 290: 792–4
   PubMed Web of Science ®Google Scholar
• Wasik M A, Beller D I. Induction of macrophage membrane interleukin expression by T-cell dependent and T-cell independent pathways is inhibited by cyclosporin A. Clin Immunol Immunopathol 1989; 52: 331–40
   PubMedGoogle Scholar
• Granelli-Piperno A, Keane M. Effects of cyclosporine A on T lymphocytes and accessory cells from human blood. Transplant Proc 1988; 20(Suppl 2)136–42
   PubMedGoogle Scholar
• Bendtzen K, Dinarello C A. Mechanism of action of cyclosporin A. Effect on T-cell-binding of interleukin 1 and antagonizing effect of insulin. Scand J Immunol 1984; 20: 43–51
   PubMedGoogle Scholar
• Harding M W, Galat A, Ueling D E, Schreiber S L. A receptor for the immunosuppressant FK506 is a cic-trans peptidylpropyl isomerase. Nature 1989; 341: 758–60
   PubMed Web of Science ®Google Scholar
• Siekiera J J, Hung S HY, Poe M, Lin C S, Sigal N H. A cytosolic binding protein for the immunosuppressant FK506 has pepti-dyl-propyl isomerase activity but is distinct from cyclosporin. Nature 1989; 341: 755–7
   PubMedGoogle Scholar
• Schreiber S L, Crabtree G R. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136–42
   PubMedGoogle Scholar
• Elliot J F, Lin Y, Mizel S B, Bleackley R C, Harnish D G, Paetkau V. Induction of interleukin 2 messenger RNA inhibited by cyclosporin A. Science 1984; 226: 1439–41
   PubMed Web of Science ®Google Scholar
• Bunjes D, Hardt C, Rollinghoff M, Wagner H. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol 1981; 11: 657–61
   PubMed Web of Science ®Google Scholar
• Kalman V K, Klimpel G R. Cyclosporin A inhibits the production of gamma interferon (IFN gamma), but does not inhibit production of virus induced IFNα/β. Cell Immunol 1983; 78: 122–9
   PubMedGoogle Scholar
• Kupiec-Weglinski J W, Filho M A, Strom T B, Tilney N L. Sparing of suppressor cells: a critical action of cyclosporine. Transplantation 1984; 38: 97–101
   PubMedGoogle Scholar
• Hess A D, Colombani P M. Mechanism of action: in vitro studies. Prog Allergy 1986; 38: 198–221
   PubMedGoogle Scholar
• The Canadian Multicentre Transplant Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation: analysis at three years. N Engl J Med 1986; 314: 1219–25
   PubMedGoogle Scholar
• Starzl T E, Klintmalm G BG, Porter K A, Iwatsuki S, Schroter G PJ. Liver transplantation with use of cyclosporin A and prednisone. N Engl J Med 1981; 305: 266–9
   PubMed Web of Science ®Google Scholar
• Reitz B A, Wallwork J L, Hunt S A, et al. Heart-lung transplantation. Successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982; 306: 557–64
   PubMed Web of Science ®Google Scholar
• Hess A D, Tutschka P J, Santos G W. Effect of cyclosporin on human lymphocyte response in vitro. III. CS inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF. J Immunol 1982; 128: 355–9
   PubMed Web of Science ®Google Scholar
• Schulak J A, Monson D, Shelby J, Corry R J. Abrogation of second-set rejection with cyclosporine. Transplantation 1983; 36: 289–93
   PubMedGoogle Scholar
• King R, Craggs R I, Gross M LP, Tompkins C, Thomas P L. Suppression of experimental allergic neuritis by cyclosporin-A. Acta Neuropathol (Berl) 1983; 59: 262–8
   PubMedGoogle Scholar
• Like A A, Anthony M, Guberski D L, Rossini A A. Spontaneous diabetes mellitus in the BB/W rat. Effects of glu-cocorticosteroids, cyclosporin A and antiserum to rat lymphocytes. Diabetes 1983; 32: 326–30
   PubMedGoogle Scholar
• McGregor A M, Rennie D P, Weetman A P, et al. The influence of cyclosporin A on experimental autoimmune thyroid diseases in the rat. Life Sci 1983; 32: 97–108
   PubMedGoogle Scholar
• Krupp P, Timonen P, Gülich A. Side effects and safety of Sandimmun in long-term treatment of transplant patients. Ciclosporin in autoimmune diseases, R Schindler. Springer-Verlag, Berlin 1985; 43–9
   Google Scholar
• Cockburn I TR, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun 1989; 2: 723–31
   PubMed Web of Science ®Google Scholar
• Hodgson H FJ. One disease or two?. Inflammatory bowel diseases. 2nd ed, R N Allan, M RB Keighley, J Alexander-Williams, C F Hawkins. Churchill Livingstone, London 1990; 121–6
   Google Scholar
• Orholm M, Munkholm P, Langholtz E, Haagen Nielsen O, Sørensen T IA, Binder V. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991; 324: 84–8
   PubMed Web of Science ®Google Scholar
• Podolski D K. Inflammatory bowel disease (first of two parts). N Engl J Med 1991; 324: 928–37
   PubMedGoogle Scholar
• Wu S WP, Pao C C, Chan J, Benedict Yen T S. Lack of mycobacterial DNA in Crohn's disease tissue. Lancet 1991; 337: 174–5
   PubMed Web of Science ®Google Scholar
• Summers R W, Switz D M, Sessions J T, et al. National cooperative Crohn's disease study: results of drug treatment. Gastroenterology 1979; 77: 847–69
   PubMed Web of Science ®Google Scholar
• Malchow H, Ewe K, Brandes J W, et al. European cooperative Crohn's disease study: results of drug treatment. Gastroenterology 1984; 86: 249–66
   PubMed Web of Science ®Google Scholar
• Pirzer U, Schönhaar A, Fleischer A, Hermann E, Meyer zum Büschenfelde K-H. Reactivity of infiltrating T lymphocytes with microbial antigens in Crohn's disease. Lancet 1991; 338: 1238–9
   PubMed Web of Science ®Google Scholar
• Jewell D P, Patel C. Immunology of inflammatory bowel disease. Scand J Gastroenterol 1985; 20(Suppl 114)119–26
   Web of Science ®Google Scholar
• Jewell D P, Snook J A. Immunology of ulcerative colitis and Crohn's disease. Inflammatory bowel diseases. 2nd ed., R N Allan, M RB Keighley, J Alexander-Williams, C F Hawkins. Churchill Livingstone, London 1990; 127–46
   Google Scholar
• Both H, Torp-Pedersen K, Kreiner S, Hendriksen C. Clinical appearance at diagnosis of ulcerative colitis and Crohn's disease in a regional patient group. Scand J Gastroenterol 1983; 18: 987–91
   PubMed Web of Science ®Google Scholar
• Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn's disease-based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26: 146–50
   PubMed Web of Science ®Google Scholar
• van Hees P AM, van Lier H JJ, van Elteren P H, et al. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut 1981; 22: 404–9
   PubMed Web of Science ®Google Scholar
• Ursing B, Aim T, Bárány T, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Results. Gastroenterology 1982; 83: 550–62
   PubMed Web of Science ®Google Scholar
• Brynskov J. The role of ciclosporin therapy in Crohn's disease. A review. Dig Dis 1991; 9: 236–44
   PubMedGoogle Scholar
• Miescher P A, Favre H, Chatelanat F, Mihatch M J. Combined steroid-cyclosporin treatment of chronic autoimmune diseases. Clinical results and assessment of nephrotoxicity by renal biopsy. Klin Wochenschr 1987; 65: 727–36
   PubMedGoogle Scholar
• Mihatsch M J, Bach J F, Coovadia H M. Cyclosporin-associated nephropathy in patients with autoimmune diseases. Klin Wochenschr 1988; 66: 43–7
   PubMedGoogle Scholar
• Brynskov J, Freund L, N0rby Rasmussen S, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989; 321: 845–50
   PubMed Web of Science ®Google Scholar
• Brynskov J, Freund L, Nørby Rasmussen S, et al. Final report on a placebo-controlled, double-blind, randomised, multicentre trial of cyclosporin treatment in active chronic Crohn's disease. Scand J Gastroenterol 1991; 26: 689–95
   PubMed Web of Science ®Google Scholar
• Present D H, Korelitz B I, Wisch N, Glass J L, Sachar D B, Pasternack B S. Treatment of Crohn's disease with 6-mer-captopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981–7
   PubMed Web of Science ®Google Scholar
• Best W R, Becktel J M, Singleton J W, Kern F, Jr. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439–44
   PubMed Web of Science ®Google Scholar
• Harvey R F, Bradshaw J M. A simple index of Crohn's-disease activity. Lancet 1980; 1: 514
   PubMed Web of Science ®Google Scholar
• van Hees P AM, van Elteren P H, van Lier H JJ, van Tongeren J HM. An index of inflammatory activity in patients with Crohn's disease. Gut 1980; 21: 279–86
   PubMed Web of Science ®Google Scholar
• Meyers S, Janowitz H D. 'Natural history' of Crohn's disease. An analytic review of the placebo lesson. Gastroenterology 1984; 87: 1189–92
   PubMed Web of Science ®Google Scholar
• Treem W R, Davis P M, Hyams J S. Cyclosporine treatment of severe ulcerative colitis in children. J Pediatr 1991; 119: 994–7
   PubMedGoogle Scholar
• Lichtinger S, Present D H. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990; 336: 16–19
   PubMedGoogle Scholar
• Brynskov J, Freund L, Campanini M C, Kampmann J P. Cyclosporin pharmacokinetics after intravenous and oral administration in patients with Crohn's disease. Scand J Gastroenterol 1992; 27: 961–7
   PubMed Web of Science ®Google Scholar
• Lichtiger S, Present D. Cyclosporin A in the treatment of severe ulcerative colitis [abstract]. Gastroenterology 1992; 102: A653
   Google Scholar
• Actis G C, Ottobrelli A, Barletti C, et al. Cyclosporin controls severe acute ulcerative colitis by abolishing the acute phase response [abstract]. Gastroenterology 1993; 104: A658
   PubMedGoogle Scholar
• Lichtiger S, Present D H, Kornbluth A, Hanauer S. Cyclosporin A in the treatment of severe, refractory ulcerative colitis: a double blinded placebo controlled trial [abstract]. Gastroenterology 1993; 104: A732
   PubMedGoogle Scholar
• Sandborn W J, Wiesner R H, Tremaine W J, LaRusso N F. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporine. Gut 1993; 34: 242–6
   PubMed Web of Science ®Google Scholar
• Brynskov J, Freund L, Stergaard Øthomsen O, Andersen C B, Nørby Rasmussen S, Binder V. Treatment of refractory ulcerative colitis with cyclosporin enemas. Lancet 1989; 1: 721–2
   PubMedGoogle Scholar
• Ranzi T, Campanini M C, Velio P, Quarto di Palo F, Bianchi P. Treatment of chronic proctosigmoiditis with cyclosporin enemas. Lancet 1989; 2: 721–2
   Google Scholar
• Sandborn W J, Tremaine W J, Schroeder K W, Batts K P, Law-Son G M. Cyclosporine (CyA) enemas for treatment-resistant, ulcerative proctosigmoiditis [abstract]. Gastroenterology 1992; 102: A690
   Google Scholar
• Winter T, Dalton H R, Merrett M N, Campbell A, Jewell D P. Cyclosporin A retention enemas in refractory distal ulcerative colitis: an open trial [abstract]. Gastroenterology 1992; 102: A947
   Google Scholar
• Shim H, Murthy S, Cooper H, Ibrahim S. Intracolonic (IC) cyclosporin (CSP) accelerates healing of experimental colitis induced by dextran sulphate [abstract]. Gastroenterology 1991; 101: A841
   Google Scholar
• Sandborn W J, Strong R M, Forland S C, Chase R E, Cutler R E. The pharmacokinetics and colonic tissue concentrations of cyclosporine after IV, oral, and enema administration. J Clin Pharmacol 1991; 31: 76–80
   PubMed Web of Science ®Google Scholar
• Sandborn W J, Tremaine W J, Schroeder K W, et al. A randomized, double-blind, placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis [abstract]. Gastroenterology 1993; 104: A775
   Google Scholar
• Drewe J, Beglinger C, Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol 1992; 33: 39–43
   PubMed Web of Science ®Google Scholar
• Grevel J, Nüesch E, Abisch E, Kutz K. Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects. Eur J Clin Pharmacol 1986; 31: 211–6
   PubMed Web of Science ®Google Scholar
• Lindholm A. Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit 1991; 13: 465–77
   PubMed Web of Science ®Google Scholar
• McMillan M A. Clinical pharmacokinetics of cyclosporin. Phar-macTher 1989; 42: 135–56
   PubMed Web of Science ®Google Scholar
• Ptachcinski R J, Venkataramanan R, Burckart G J. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986; 11: 107–32
   PubMed Web of Science ®Google Scholar
• Brynskov J, Binder V, Riis P, et al. Low-dose cyclosporin for Crohn's disease: implications for clinical trials. Aliment Pharmacol Ther 1989; 3: 135–42
   PubMed Web of Science ®Google Scholar
• Lennard-Jones J. Toward optimal use of corticosteroids in ulcerative colitis and Crohn's disease. Gut 1983; 24: 177–81
   PubMed Web of Science ®Google Scholar
• Allam B F, Tillman J E, Thomson T J, Crossling F T, Gilbert L M. Effective intravenous cyclosporin therapy in a patient with severe Crohn's disease on parenteral nutrition. Gut 1987; 28: 1166–9
   PubMedGoogle Scholar
• Marbet U A, Gyr K, Stadler G A. Controlled study of cyclosporin versus corticosteroids in acute Crohn's disease: methodology and early findings. Ciclosporin in autoimmune diseases, R Schindler. Springer-Verlag, Berlin 1985; 188–9
   Google Scholar
• Present D, Lichtiger S. The efficacy of cyclosporin in the treatment of the fistula of Crohn's disease [abstract]. Gastroenterology 1992; 102: A680
   Google Scholar
• Smith M B, Hanauer S B. Rapid closure of Crohn's disease fistulae with intravenous cyclosporin [abstract]. Eur J Gastroenterol Hepatol 1991; 3(Suppl 1)S2
   Google Scholar
• Roberts R, Sketris I S, Abraham I, Givner M L, MacDonald A S. Cyclosporine absorption in two patients with short bowel syndrome. Drug Intell Clin Pharm 1988; 22: 570–2
   PubMedGoogle Scholar
• Lake K D. Management of drug interactions with cyclosporin. Pharmacotherapy 1991; 11: 110S–8S
   Google Scholar
• Winer B J. Statistical principles in experimental design. 2nd ed. McGraw-Hill, New York 1971; 855–9
   Google Scholar
• Prummel M F, Mourits M, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 1989; 321: 1353–9
   PubMed Web of Science ®Google Scholar
• Klintmalm G, Säwe J. High dose methylprednisolone increases plasma cyclosporin levels in renal transplant patients. Lancet 1984; 1: 731
   PubMedGoogle Scholar
• öst L. Impairment of prednisolone metabolism by cyclosporin treatment in renal graft recipients. Transplantation 1987; 44: 533–5
   PubMed Web of Science ®Google Scholar
• Frey F J, Schnetzer A, Horber F F, Frey B M. Evidence that cyclosporine does not affect the metabolism of prednisolone after renal transplantation. Transplantation 1987; 43: 494–8
   PubMedGoogle Scholar
• Ubhi C S, Woodhouse L, Giles G R. Interaction of intravenous methylprednisolone with oral cyclosporin. Nephrol Dial Transplant 1990; 5: 376–8
   PubMedGoogle Scholar
• Lauritsen K. Drug treatment and formation of eicosanoids in patients with chronic inflammatory bowel disease [thesis]. Lægeforeningens forlag, Copenhagen 1989
   Google Scholar
• Mihatsch M J, Thiel G, Ryffel B. Morphology of ciclosporin nephropathy. Prog Allergy 1986; 38: 447–65
   PubMedGoogle Scholar
• Klintmalm G, Bohman S-O, Sundelin B, Wilczek H. Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: beneficial effect of low doses in early post-transplant period. Lancet 1984; 2: 950–4
   PubMed Web of Science ®Google Scholar
• Myers B D, Ross J, Newton L, Luetscher J, Perlroth M. Cyclo-sporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699–705
   PubMed Web of Science ®Google Scholar
• Feutren G, Mihatsch M J. for the International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med 1992; 326: 1654–60
   PubMed Web of Science ®Google Scholar
• Jörgensen Dahlager J-I, Ladefoged J. The sensitivity and specificity of hippuran renography as a diagnostic investigation of renal transplant rejection. Dan Med Bull 1987; 34: 50–2
   PubMedGoogle Scholar
• Thomsen H S, Levin Nielsen S, Larsen S, Løkkegaard H. Renography and biopsy-verified acute rejection in renal allo-transplanted patients receiving cyclosporin A. Eur J Nucl Med 1987; 12: 473–6
   PubMedGoogle Scholar
• Brynskov J, Thomsen H, Levin-Nielsen S. Renographic monitoring of renal function in patients with Crohn's disease treated with low dose cyclosporin: a controlled study. Br Med J 1990; 300: 1438–9
   PubMedGoogle Scholar
• Dieperink H. Cyclosporin A nephrotoxicity [thesis]. Dan Med Bull 1989; 36: 235–47
   PubMedGoogle Scholar
• Lobo A J, Juby L D, Foster P N, Rothwell J, Smith A H, Axon A TR. Oral cyclosporin and renal function in Crohn's disease [abstract]. Gut 1989; 30: A1480
   Google Scholar
• International Kidney Biopsy Registry of Cyclosporin A (San-dimmun) in Autoimmune Diseases. Kidney biopsies in control or cyclosporin A-treated psoriatic patients. Br J Dermatol 1990; 122(Suppl 36)95–100
   PubMedGoogle Scholar
• Thomson A W, Neild G H. Cyclosporin: use outside transplantation. Promising, but long term follow up is essential. Br Med J 1991; 302: 4–5
   PubMed Web of Science ®Google Scholar
• O'Donoghue D P, Dawson A M, Powell-Tuck J, Bown R L, Lennard-Jones J E. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978; 2: 955–7
   PubMed Web of Science ®Google Scholar
• Ginsberg A L. The azathioprine controversy. J. E. Lennard-Jones vs John Singleton. Dig Dis Sci 1981; 26: 364
   PubMedGoogle Scholar
• Lennard-Jones J. Azathioprine and 6-mercaptopurine have a role in the treatment of Crohn's Disease. Dig Dis Sci 1981; 26: 364–8
   PubMed Web of Science ®Google Scholar
• Singleton J W. Azathioprine has a very limited role in the treatment of Crohn's disease. Dig Dis Sci 1981; 26: 368–71
   PubMedGoogle Scholar
• Allison M C, Pounder R E. Cyclosporin for Crohn's disease. Aliment Pharmacol Ther 1987; 1: 39–43
   PubMedGoogle Scholar
• Lobo A J, Juby L D, Rothwell J, Poole T W, Axon A TR. Long-term treatment of Crohn's disease with cyclosporin: The effect of a very low dose on maintenance of remission. J Clin Gastroenterol 1991; 13: 42–5
   PubMedGoogle Scholar
• Archambault A, Feagan B, Fedorak R, et al. The Canadian Crohn's relapse prevention trial [abstract]. Gastroenterology 1992; 102: A591
   Google Scholar
• Brynskov J, Tvede N. Plasma interleukin-2 and a soluble/ shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin. Gut 1990; 31: 795–9
   PubMed Web of Science ®Google Scholar
• Brynskov J, Tvede N, Vilien M, Andersen C B. Increased concentrations of interieukin 1β, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease. Gut 1992; 33: 55–8
   PubMed Web of Science ®Google Scholar
• Macleod A M, Thomson A W. FK 506: an immunosuppressant for the 1990s?. Lancet 1991; 337: 25–7
   PubMed Web of Science ®Google Scholar
• Kay J E, Kromwel L, Doe S EA, Denyer M. Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 1991; 72: 544–9
   PubMed Web of Science ®Google Scholar
• Hiestand P C, Graber M, Hurtenbach U, et al. The new cyclosporine derivative, SDZ IMM 125: in vitro and in vivo pharmacological effects. Transplant Proc 1992; 24(Suppl 2)31–8
   PubMedGoogle Scholar
• Bendtzen K, Diamant M, Faber V. Fusidic acid, an immunosuppressive drug with functions similar to cyclosporin A. Cytokine 1990; 2: 423–9
   PubMedGoogle Scholar
• Langholtz E, Brynskov J, Freund L G, Bendtzen K. Fusidic acid for Bechet's colitis: a novel approach to T cell specific immunosuppressive therapy. Dan Med Bull 1991; 38: 284
   PubMedGoogle Scholar
• Langholtz E, Brynskov J, Bendtzen K, Vilien M, Binder V. Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin. Aliment Pharmacol Ther 1992; 6: 495–502
   PubMedGoogle Scholar
• Brynskov J, Bagge Hansen M, Reimert C, Bendtzen K. Inhibitor of interieukin-1α and interieukin- 1β-induced T-cell activation in serum of patients with active Crohn's disease. Dig Dis Sci 1991; 36: 737–42
   PubMedGoogle Scholar
• Arend W P. Interieukin 1 receptor antagonist. A new member of the interieukin 1 family. J Clin Invest 1991; 88: 1445–51
   PubMed Web of Science ®Google Scholar
• Isaacs K I, Sartor R B, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992; 103: 1587–95
   PubMed Web of Science ®Google Scholar
• Emmrich J, Seyfarth M, Fleig W E, Emmrich F. Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody [abstract]. Gastroenterology 1992; 102: A620
   Google Scholar
• Meyer L, Sachar D B, Present D H, et al. Randomized, double-blind, placebo-controlled trial of hydroxychloroquine (Plaquenil) in the treatment of ulcerative colitis [abstract]. Gastroenterology 1992; 102: A661
   PubMedGoogle Scholar
• Siegel S, Castellan N J. Nonparametric statistics for the behavioral sciences. 2nd ed. McGraw-Hill, New York 1988; 184–9
   Google Scholar